News
CMMB
--
0.00%
--
Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021
 
Benzinga · 2d ago
TLRY, ET, ROKU and NET among premarket gainers
iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on
Seekingalpha · 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 2d ago
Oppenheimer Initiates Coverage On Chemomab Therapeutics with Outperform Rating, Announces Price Target of $42
Oppenheimer analyst Jeff Jones initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform rating and announces Price Target of $42.
Benzinga · 2d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 2d ago
64 Biggest Movers From Yesterday
Gainers
Benzinga · 4d ago
Chemomab Therapeutics Files Shelf of Up to $200 Million in Securities
MT Newswires · 6d ago
BRIEF-Chemomab Therapeutics Files For Mixed Shelf Of Up To $200 Mln– SEC Filing
reuters.com · 04/30 21:11
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 04/27 20:57
Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phas...
PR Newswire · 04/26 11:30
Chemomab Therapeutics Enrolls First Patient in Non-Alcoholic Steatohepatitis Study
MT Newswires · 04/26 06:58
Update: Chemomab Therapeutics Plummets 17.5% After Filing Shelf of Up to 7.2 Million ADSs on Behalf of Selling Shareholders
MT Newswires · 04/16 13:45
Wall Street Holds on to Gains Midday as Dow, S&P Hit New Highs
MT Newswires · 04/16 13:07
Chemomab Therapeutics Files Shelf of Up to About 7.2 Million ADSs on Behalf of Selling Shareholders
MT Newswires · 04/16 03:08
BRIEF-Chemomab Files For Resale Of Up To 7.2 Million ADSs By Selling Shareholders
reuters.com · 04/15 20:18
BRIEF-Chemomab Announces Four New Appointments To Board
reuters.com · 03/29 13:22
Chemomab Announces Four New Appointments to the Board of Directors and Completion of PIPE Financing
TEL-AVIV, Israel, March 29, 2021 /PRNewswire via COMTEX/ -- TEL-AVIV, Israel, March 29, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a...
PR Newswire - PRF · 03/29 13:00
SVRA, ZYNE, CANF and CLSK among midday movers
Gainers: SunLink Health Systems (SSY) +219%.Can-Fite BioPharma (CANF) +53%.Savara (SVRA) +37%.Fintech Acquisition (FTCVU) +31%.New Fortress Energy (NFE) +27%.Lizhi (LIZI) +26%.Enzo Biochem (ENZ) +25%.iSun (ISUN) +23%.Anchiano Therapeutics (ANCN) +21%.Optim...
Seekingalpha · 03/16 16:41
SunLink Health Systems, Can-Fite BioPharma leads healthcare gainers; Solid Biosciences, Zynerba Pharmaceuticals among major losers
Gainers: SunLink Health Systems (SSY) +161%, Can-Fite BioPharma (CANF) +61%, Streamline Health Solutions (STRM) +56%, Anchiano Therapeutics (ANCN) +40%, Enzo Biochem (ENZ) +39%.Losers: Solid Biosciences (SLDB) -31%, Zynerba Pharmaceuticals (ZYNE) -21%, Che...
Seekingalpha · 03/16 14:58
Mid-Morning Market Update: Markets Mixed; Jabil Beats Q2 Views
Following the market opening Tuesday, the Dow traded down 0.17% to 32,895.91 while the NASDAQ rose 0.80% to 13,567.73. The S&P also rose, gaining 0.23% to 3,978.07.
Benzinga · 03/16 14:36
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.